Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative

Author:

Teske Arco J.1ORCID,Moudgil Rohit2ORCID,López-Fernández Teresa3ORCID,Barac Ana4ORCID,Brown Sherry Ann5,Deswal Anita6ORCID,Neilan Tomas G.7ORCID,Ganatra Sarju8,Abdel Qadir Husam9,Menon Venu2ORCID,Sverdlov Aaron L.10ORCID,Cheng Richard K.11ORCID,Makhoul Silvia12ORCID,Ghosh Arjun K.131415ORCID,Szmit Sebastian16ORCID,Zaha Vlad17ORCID,Addison Daniel18ORCID,Zhang Lili19,Herrmann Joerg20,Chong Jun H.21,Agarwala Vivek22ORCID,Iakobishvili Zaza23ORCID,Guerrero Patricia24,Yang Eric H.25ORCID,Leja Monika26,Akhter Nausheen27ORCID,Guha Avirup28ORCID,Okwuosa Tochukwu M.29ORCID,Silva Carolina Carvalho30,Collier Patrick2ORCID,DeCara Jeanne31ORCID,Bauer Brenton32ORCID,Lenneman Carrie E.33,Sadler Diego34ORCID

Affiliation:

1. Department of Cardiology, University Medical Centre Utrecht, The Netherlands (A.J.T.).

2. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Foundation, OH (R.M., V.M., P.C.).

3. Hospital Universitario La Paz, Madrid, Spain (T.L.-F.).

4. Medstar Heart Institute, Georgetown University, WA, DC (A.B.).

5. Medical College of Wisconsin, Milwaukee (S.A.B.).

6. MD Anderson Cancer Center, Houston, TX (A.D.).

7. Massachusetts General Hospital, Harvard Medical School, Boston (T.G.N.).

8. Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA (S.G.).

9. University of Toronto, Canada (H.A.Q.).

10. Newcastle Centre of Excellence in Cardio-Oncology, Calvary Mater Newcastle, Hunter Medical Research Institute, John Hunter Hospital, University of Newcastle, NSW, Australia (A.L.S.).

11. University of Washington Medical Center, Seattle (R.K.C.).

12. Hospital Juan A Fernández/Hospital Británico de Buenos Aires Buenos Aires, Argentina (S.M.).

13. Barts Heart Centre, St Bartholomew’s Hospital (A.K.G.), London, United Kingdom.

14. University College London Hospital (A.K.G.), London, United Kingdom.

15. Hatter Cardiovascular Institute (A.K.G.), London, United Kingdom.

16. Centre of Postgraduate Medical Education, Warsaw, Poland (S.S.).

17. UT Southwestern Medical Center, Dallas, TX (V.Z.).

18. Ohio State University, Columbus (D.A.).

19. Montefiore Medical Center/Albert Einstein College of Medicine, NY (L.Z.).

20. Mayo Clinic, Rochester, MN (J.H.).

21. National Heart Centre, Singapore (J.H.C.).

22. Narayana Superspeciality Hospital and Cancer Institute and RN Tagore Cancer Center, Kolkata, India (V.A.).

23. Department of Cardiology, Tel Aviv Jaffa District Clalit Health Services, Tel Aviv, Israel (Z.I.).

24. AdventHealth, Orlando, FL (P.G.).

25. University of California Los Angeles (E.H.Y.).

26. University of Michigan Medical Center, Ann Arbor (M.L.).

27. Northwestern University Feinberg School of Medicine, Chicago, IL (N.A.).

28. Cardio-Oncology Program, Department of Medicine, Georgia Cancer Center, Medical College of Georgia at Augusta University, GA (A.G.).

29. Rush University Medical Center, Chicago, IL (T.M.O.).

30. Rede D’Or Hospital Group, Sao Paulo, Brazil (C.C.S.).

31. University of Chicago School of Medicine, IL (J.D.C.).

32. COR Healthcare Associates/Torrance Memorial Medical Center, CA (B.B.).

33. University of Alabama at Birmingham (C.E.L.).

34. Cleveland Clinic Florida, Weston (D.S.).

Abstract

BACKGROUND: Global collaboration in cardio-oncology is needed to understand the prevalence of cancer therapy-related cardiovascular toxicity in different risk groups, practice settings, and geographic locations. There are limited data on the socioeconomic and racial/ethnic disparities that may impact access to care and outcomes. To address these gaps, we established the Global Cardio-Oncology Registry, a multinational, multicenter prospective registry. METHODS: We assembled cardiologists and oncologists from academic and community settings to collaborate in the first Global Cardio-Oncology Registry. Subsequently, a survey for site resources, demographics, and intention to participate was conducted. We designed an online data platform to facilitate this global initiative. RESULTS: A total of 119 sites responded to an online questionnaire on their practices and main goals of the registry: 49 US sites from 23 states and 70 international sites from 5 continents indicated a willingness to participate in the Global Cardio-Oncology Registry. Sites were more commonly led by cardiologists (85/119; 72%) and were more often university/teaching (81/119; 68%) than community based (38/119; 32%). The average number of cardio-oncology patients treated per month was 80 per site. The top 3 Global Cardio-Oncology Registry priorities in cardio-oncology care were breast cancer, hematologic malignancies, and patients treated with immune checkpoint inhibitors. Executive and scientific committees and specific committees were established. A pilot phase for breast cancer using Research Electronic Data Capture Cloud platform recently started patient enrollment. CONCLUSIONS: We present the structure for a global collaboration. Information derived from the Global Cardio-Oncology Registry will help understand the risk factors impacting cancer therapy-related cardiovascular toxicity in different geographic locations and therefore contribute to reduce access gaps in cardio-oncology care. Risk calculators will be prospectively derived and validated.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3